In ongoing collaborative studies funded by NIAID and NHLBI, we are determining the ability of Siglec-8/Siglec-F antibodies and ligands to limit allergic and other detrimental responses involving eosinophils and mast cells in vitro and in vivo. Studies have led to the discovery of 6'-sulfated sialyl Lewis X as a candidate ligand for Siglec-8 and Siglec-F. Other experiments are characterizing natural Siglec-8/Siglec-F ligands, determining their tissue expression, and exploring the contributions of various glycosyltranferases needed to generate these unique glycan ligands, and consequences of their deficiency. Because of the selective expression pattern of Siglec-8 only on eosinophils, mast cells and basophils, we are leveraging this specificity to develop Siglec-8-based drug targeting strategies. Some of these efforts include the development and use of newly created transgenic mice that express Siglec-8 on their mast cells and eosinophils.
Additionally, given our expertise in mast cell and basophil function, we are interested in discovering and employing new strategies to prevent anaphylaxis, as can occur in food, drug and insect sting allergy.
Learn more about our projects using the links below: